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Summary
Background: Atrial ﬁbrillation (AF) is the most common sustained arrhythmia affecting over
700,000 individuals in Japan and 2.2 million in the USA. The proper management of patients
with AF is critical due to the well-documented association with heart failure and stroke. A
strategy to better deﬁne the emergency department (ED) management, admission decisions,
and spectrum of risk from low to high is needed.
Methods and subjects: The atrial ﬁbrillation and ﬂutter outcomes and risk determination investi-
gation is a prospective, observational cohort study to develop a multivariable clinical prediction
rule that accurately estimates risk for adverse outcomes in patients presenting to the ED with
symptomatic AF. We will enroll 430 patients at 2 sites who present to the ED with symptomatic
AF deﬁned as a new or established diagnosis of AF or atrial ﬂutter that require ED evaluation
for a complaint thought related to their rhythm disturbance. The study’s endpoint is to develop
an accurate, objective, internally validated, reliable clinical prediction rule to risk-stratify ED
patients presenting with AF exacerbations. The rule will incorporate patient history and exam-
ination ﬁndings and laboratory studies obtained upon ED presentation, as well as trends over
the ﬁrst 2 h of care. This investigation’s primary outcome is the incidence of any AF-related
adverse event at 5 days and 30 d
study was registered at Clinicalt
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Introduction
Atrial ﬁbrillation (AF), the most common sustained cardiac
arrhythmia in clinical practice affects more than 700,000
individuals in Japan and 2.2 million in the USA [1,2]. AF is
associated with a 5-fold increase in the risk of stroke and
1.5- to 1.9-fold increased risk of death [1—6]. Nearly 1% of
all US emergency department (ED) visits are for complaints
related to AF [7]. The ability to accurately risk-stratify AF
patients presenting to the ED is poor and more than 65% of
these ED visits result in hospital admission and contribute to
healthcare expenditures ranging from $6 to $26 billion [8,9].
Studies have shown substantial variations in the ED treat-
ment of AF [10] and that nearly half of these admissions
could be avoided and patients safely discharged home
[11—14]. These have incorporated ED practice guidelines,
observation units, and expedited cardioversion, but have
suffered from retrospective methodology, small sample
sizes, and a focus on identiﬁcation of high-risk features only.
A strategy to better deﬁne the ED management, admission
decisions, and spectrum of risk from low to high is sorely
needed [15]. A review of 12-years of ED visits for AF from the
National Hospital Ambulatory Medical Care Survey (NHAMCS)
database found that admitted patients with symptomatic AF
were similar to those discharged home from the ED with
respect to age, sex, comorbidities, and whether ED rate
control, cardioversion or anticoagulation were attempted
[15].
We recently reported the ﬁrst clinical prediction model
for predicting 30-day adverse events in ED patients with
symptomatic AF [16]. This rule, however, was derived from
a retrospective cohort sample and we were not able to con-
trol for all potential confounders and effect modiﬁers. The
atrial ﬁbrillation and ﬂutter outcomes and risk determina-
tion (AFFORD) study’s objective is to develop and internally
validate a multivariable clinical prediction rule based on
established clinical and biostatistical standards [17—22]
that accurately estimates risk for adverse outcomes in ED
patients with symptomatic AF. This paper presents the ratio-
nale and the design of the AFFORD study.
Methods
Study design
The AFFORD study (Clinicaltrials.gov identiﬁer:
NCT01138644) is a prospective, observational cohort
study designed to develop and validate a multivariable
clinical prediction rule for ED patients with symptomatic
AF or atrial ﬂutter. Fig. 1 details a schematic ﬂow chart
for AFFORD patient enrollment and data collection. The
study’s primary outcome is the incidence of any AF-related
adverse event at 5 days and 30 days.
The AFFORD study will enroll subjects at 2 centers: a sin-
gle, tertiary care, university-afﬁliated hospital’s adult ED
(55,000 adult ED visits/year) and a large, academic, veter-
ans administration hospital ED (20,000 ED visits/year). We
will enroll a convenience sample of 430 adult ED patients
over a period of 36months. The inclusion and exclusion cri-
teria are detailed in Table 1. The study investigators will
screen all ED patients presenting with signs (e.g. tachy-
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ardia, dyspnea) and symptoms (e.g. palpitations, chest
ain, shortness of breath, weakness, lightheadedness, pre-
yncope, or syncope) consistent with potential diagnoses
f symptomatic AF or atrial ﬂutter. The diagnosis of AF
equires electrocardiographic evidence of AF or atrial ﬂut-
er patterns performed on the date of the patient encounter
n the ED. The electrocardiographic diagnosis of AF or
trial ﬂutter will be veriﬁed with an ED attending prior
o enrollment. The ﬁnal electrocardiogram interpretation
s subsequently conﬁrmed by an independent cardiologist
eview of the electrocardiogram. We will withdraw patients
ho are erroneously diagnosed with AF or atrial ﬂutter by
he ED attending interpretation but later determined to
ave an alternative heart rhythm by the cardiologist inter-
retation. We will use the operational deﬁnition for the
ubtypes of AF (new onset, paroxysmal, persistent, and
ermanent AF) as deﬁned by the American College of Car-
iology/American Heart Association Task Force on Practice
uidelines and the European Society of Cardiology Commit-
ee for Practice Guidelines and Policy Conferences [23—25].
tudy procedures
atients who consent to participate will be asked a series
f standardized questions and candidate predictors will be
btained through direct questioning of the subject and
eview of the subject’s electronic medical record. We will
ollect and process blood and urine specimens for labora-
ory testing. Medical record reviews will be conducted using
tandardized criteria and their accuracy will be veriﬁed by
repeat review [26]. The investigators will be blinded to
patient’s outcome status for the medical record reviews
nd will use a data dictionary with precise deﬁnitions for the
andidate predictors and outcomes created prior to study
nitiation.
Participants will be contacted at 5 days and 30 days fol-
owing their initial ED visit to assess for adverse outcomes.
he 5-day follow up period was chosen to enhance the pro-
osed prediction rule’s face validity and represent a more
ealistic association of adverse events and the treatment
eceived at the ED visit. For comparison to other studies,
e will also document follow-up at 30 days. Investigators
ill use a standard telephone communication data collec-
ion form for all interviews. In addition to the telephone
nterviews, the investigators will review the patient’s elec-
ronic medical record and the Social Security Death Index to
ssess for outcomes. Admitted patients will receive follow-
p telephone communication at both 5 days and 30 days from
he date of their initial ED visit. If the patient is hospi-
alized for more than 5 days, the investigators will review
he admission medical records and document any adverse
vents.
andidate predictor variables
redictor variables for an AF prediction rule must be read-
ly available to physicians in the routine management of ED
atients with symptomatic AF and enter the model in the
ame temporal manner that the predictor would be avail-
ble in the clinical arena [17—22,27]. We will limit the AF
rediction rule to include only candidate predictors whose
126 T.W. Barrett et al.
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Eig. 1 Schematic ﬂow chart showing the process for atrial
nrollment and data collection. AF, atrial ﬁbrillation; ED, emer
nformation is available within the ﬁrst 2 h of ED manage-
ent. This time limitation accurately mirrors ED clinical
ractice and will signiﬁcantly increase the rule’s utility in
eal practice. We pre-selected the primary candidate pre-
ictor variables for the AFFORD study, listed in Table 2, in
ccordance with established standards [17—22,27]. Detailed
eﬁnitions for each of these variables are available in
lectronic supplemental table. However, because of the
ynamic nature of this research area and the length of time
ver which patients are being recruited, we are also collect-
ng data on additional variables as well [28—32].
tudy outcomeshe primary outcome for the AFFORD study is measuring the
ncidence of adverse events at 5 days and 30 days from the
D evaluation. A hierarchical listing of these speciﬁc adverse
vents with a priori proposed ordinal scale severity value
T
a
C
tillation and ﬂutter outcomes and risk determination patient
y department.
ssignments is presented in Fig. S1. The accurate deter-
ination of whether the adverse events are related to AF
s of utmost importance for this study. Two faculty investi-
ators, specialists in arrhythmia and emergency medicine,
ill review each reported 5-day and 30-day adverse event
nd make a consensus determination on whether it was
F-related. A third senior arrhythmia faculty investigator
ill adjudicate any disagreements between the two pri-
ary reviewers. This consensus outcome determination will
e made prior to any analysis of the candidate predictor
ariables.
thical conducthe study is conducted with Good Clinical Practice and in
ccordance with our institutional and federal Responsible
onduct of Research guidelines. Our medical center institu-
ional review board approved the study protocol prior to
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Table 1 Atrial ﬁbrillation and ﬂutter outcomes and risk determination: inclusion and exclusion criteria.
Inclusion criteria
ED patients 18 years and older
Have a documented diagnosis of AF or atrial ﬂutter on an ED electrocardiogram or rhythm strip
Present with signs (tachycardia, dyspnea) or symptoms (palpitations, chest pain, shortness of breath, weakness,
lightheadedness, pre-syncope, or syncope) consistent with primary symptomatic AF.
We will also include patients whose primary complaint is not directly related to their AF diagnosis (e.g. evaluation for febrile
illness, gastrointestinal complaint, injury) BUT have a secondary complaint consistent with symptomatic AF that requires
ED evaluation.
These situations will include the following: new AF diagnosis, AF associated with inadequate rate control (deﬁned as resting
heart rate greater than 100 bpm), AF associated with heart failure symptoms, AF in the setting of CVA or TIA, AF associated
with other thromboembolic complications. ED patients who present with complaints unrelated to their AF (e.g. sprained
ankle, pharyngitis) and have adequately rate (<100 bpm at rest) or rhythm controlled-AF will not be eligible for inclusion on
that ED visit.
Provided informed consent and signed Health Insurance Portability and Accountability Act waiver for collection of private
health data.
Exclusion criteria
Patients unwilling or unable to give informed consent
Previously enrolled in this study
Seek ED treatment for a primary or secondary complaint not related to AF or atrial ﬂutter.
There will be no exclusion by race, gender or ethnic characteristics.
AF, atrial ﬁbrillation; ED, emergency department.
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Wthe commencement of study enrollment. At the time of
manuscript submission, we are awaiting formal review of
our study protocol by the Veterans Administration Hospital
Institutional Review Board.
Statistical analysis
The development of an accurate, validated clinical pre-
diction rule requires that there must be 15 subjects or
events per degree of freedom for the rule to be reliable
and not at risk of overﬁtting. Thus for the 27 degrees
of freedom noted in Table 2, we should enroll 405 sub-
jects [17,27]. We increased the sample size estimate
to 430 subjects to account for a potential 5% loss to
follow-up. The entire sample will be used in model devel-
opment.
Analysis strategy
The investigators assessing the presence of each outcome
event will be masked to the predictor variables and vice
versa. This is done to adhere to the standards for develop-
ment of clinical prediction rules. The statistical analysis is
focused on the development of multivariable models relat-
ing predictor variables to the outcome events with the goal
of developing the AF prediction rule. Candidate models may
then be used to estimate adjusted effects of predictor vari-
ables of interest, after controlling for the effects of other
predictors [17—23,27].
Potential confounding variables of the rule include demo-
graphic features, access to medical care, home medication
regimen, other comorbidities, and other predictor variables.
n
a
W
oe will evaluate for confounding by comparing the bivari-
te (unadjusted) regression coefﬁcients with the adjusted
oefﬁcients of the multiple regression models. Our rule
ill incorporate effect modiﬁers in addition to our primary
utcomes. These effect modiﬁers are listed in Electronic
upplemental ﬁgure.
The AFFORD prediction rule development will follow
he established strategies and include the following criti-
al steps [17—23,27,33]. We clearly identiﬁed a priori the
elationships of interest and deﬁned the candidate predic-
or variables and outcome variables for each multivariable
egression analysis. Regression splines will be used to relax
he linearity assumption of continuous predictors [34]. Ide-
lly, we would have no missing data, especially for key
redictors. When we have missing data on predictor vari-
bles, we will use multiple imputation techniques to make
ptimal use of partial information recorded for each sub-
ect [35]. We will incorporate pre-speciﬁed interactions
hen biologically plausible. The composite outcome vari-
bles (incidence of 5-day and 30-day adverse events) have
een structured as a hierarchy of ordinal outcomes and pro-
ortional odds logistic regression will be used for analysis
36]. The predictive accuracy of the rule will be measured
y calculating the rule’s discrimination using area under
eceiver operating characteristic (ROC) curve or concor-
ance (c-index). We will calculate the rule’s calibration
nd demonstrate it with a smooth nonparametric calibration
urve or scatter plot of predicted versus observed outcome.
e will create these plots for a variety of cutoffs in the ordi-
al outcome level. We will internally validate the calibration
nd discrimination of the rule using bootstrap resampling.
e will review the AFFORD prediction rule with cardiol-
gists and emergency physicians who are masked to the
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Table 2 Atrial ﬁbrillation and ﬂutter outcomes and risk determination candidate predictors.
Predictor Ascertainment and
deﬁnition
Operational
deﬁnition
Typea Degrees of
freedom
Age Interview and EMR
review
Value in years c 3
Sex Interview Female/male d 1
2 h resting heart rate Bedside monitor Value in beats per
minute
c 3
Maximum heart rate
in ﬁrst 2 h of ED
treatment
Bedside monitor Value in beats per
minute
C 3
Requires iv drug
infusion
Review of EMR and
electronic order
tracker
Yes/no D 1
Heart failure EMR and Echo results Yes/no D 1
Diabetes Interview and EMR
review
Yes/no D 1
Valvular heart disease EMR and Echo results Yes/no D 1
History of CVA or TIA Interview and EMR
review
Yes/no D 1
Takes >2 AV node
blocker
medications
Interview and EMR
review
Yes/no D 1
Home warfarin use Interview and EMR
review, INR
Yes/no D 1
Home digoxin use Interview and EMR
review, digoxin level
Yes/no D 1
Dyspnea in ED Interview and EMR
review
Yes/no D 1
Palpitations in ED Interview and EMR
review
Yes/no D 1
Atrial ﬂutter on ECG Review of ECG and
EMR
Yes/no D 1
BNP Core laboratory test Laboratory value C 2
BUN Core laboratory test Laboratory value C 2
Troponin I Core laboratory test Laboratory value C 2
Overall degrees of
freedom
27
a Type of variable: c, continuous; d, dichotomous; AV, atrioventricular; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen;
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reported to be between 3 and 5% [12—14]. These recidivism
rates suggest that the current criteria used by emergencyCVA, cerebrovascular accident; ECG, electocardiography; Echo, ec
record; INR, international normalized ratio; TIA, transient ischem
ule’s predictive discrimination (c index). We will derive
ultiple scoring systems based on the regression coefﬁ-
ients, and trial these systems with clinicians to choose the
ost ‘‘sensible’’ rule. This will maximize the AFFORD rule’s
otential impact factor.
Future prospective, international, multicenter investi-
ations will be planned to externally validate the AFFORD
rediction rule.
imelines
he ﬁrst AFFORD patient was enrolled on June 8, 2010 and
t time of manuscript submission, 221 patients have been
nrolled. We anticipate completing patient recruitment by
pril 2014 and ﬁnalizing prediction rule development and
nternal validation by December 2014.
p
drdiography; ED, emergency department; EMR, electronic medical
ack.
iscussion
mergency medicine research has focused on develop-
ng alternatives to admitting patients through the use of
ractice policies and observation units. Physicians have
ccepted prior clinical decision rules into their practice,
o an accurate AF prediction rule would be valuable to
linical practice. The exceedingly high admission rate sug-
ests that physicians are not conﬁdent stratifying patients
o ‘‘low risk’’ and thus choose to admit the vast major-
ty of patients with symptomatic AF. In addition, the ED
eturn rate within 7 days among discharged patients ishysicians to identify patients safe for ED discharge are
eﬁcient.
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[Atrial ﬁbrillation and ﬂutter outcomes and risk determinatio
The proposed project is unique in that most AF prediction
rules have focused on long-term thromboembolic events,
maintenance of sinus rhythm, or overall mortality. The ED-
based rules have chosen to predict hospital admission; no
prospective study has yet identiﬁed the ‘‘low-risk’’ patient
who can be safely discharged from the ED. Furthermore,
there is a lack of AF prediction rules that adhere to the
strict study design and biostatistical methodology advocated
by prognostic modeling experts.
Several key aspects of the study are strengths. We will
collect most data in a real-time, prospective manner thus
limiting the number of missing values of key candidate
predictors that are vital to development of a reliable pre-
diction rule. We will incorporate information available to
the physician within the ﬁrst 2 h of ED treatment. This time
limitation accurately reﬂects actual management and dis-
position decision-making. The AFFORD rule will include the
most up-to-date diagnostic studies that have demonstrated
prognostic association with AF and associated cardiovascu-
lar diseases. We will develop a risk stratiﬁcation rule for
the entire AF population. Speciﬁcally, we are interested in
the low-risk group as this identiﬁcation might signiﬁcantly
decrease hospital admissions. This study includes an addi-
tional 5-day adverse outcome measurement period that is
more likely associated with ED management of the patient’s
acute AF episode than the common 30-day measurements.
In conclusion, the AFFORD study’s objective is to develop
an accurate, objective risk-stratiﬁcation rule for ED patients
with symptomatic AF. An AF prediction rule is a necessary
addition to the acute management of AF in order to improve
patient care and safety, more efﬁciently utilize healthcare
resources, provide emergency physicians with a standard-
ized decision aid for risk stratifying this common disease,
and further clinical research into AF treatment and preven-
tion.
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